New drug shows promise in controlling rare blood disorder
NCT ID NCT06578949
Summary
This completed Phase 3 study tested whether the drug ravulizumab could effectively control paroxysmal nocturnal hemoglobinuria (PNH), a rare and serious blood disease, in Chinese adults who hadn't previously tried this type of medication. The trial involved 18 participants and measured how well the drug reduced disease activity markers and prevented blood transfusions over 26 weeks. Researchers also monitored side effects and how the drug affected participants' fatigue levels and overall blood health.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Beijing, CN-100730, China
-
Research Site
Guangzhou, 510100, China
-
Research Site
Hangzhou, 310003, China
-
Research Site
Nantong, 226001, China
-
Research Site
Shanghai, 200040, China
-
Research Site
Tianjin, 300020, China
-
Research Site
Tianjin, 300050, China
-
Research Site
Wuhan, 430022, China
Conditions
Explore the condition pages connected to this study.